基于细胞的疗法可以将心力衰竭改变的右心室蛋白质组逆转为疾病前的状态
Nour Makkaoui1,2, Vidhya Prasad1,2, Pritha Bagchi3
1Division of Pediatric Cardiology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Stem cell research & therapy
|November 13, 2024
概括
介质细胞 stromal 细胞 (MSC) 和某些c-kit 阳性细胞 (CPC) 可以逆转右心室压力过载中的蛋白质变化. 这种细胞疗法在疾病后恢复心脏功能方面表现有前途.
科学领域:
- 心血管研究研究心血管研究
- 再生医学是一种再生医学.
- 蛋白质组学是指蛋白质组学.
背景情况:
- 先天性心脏缺陷会导致右心室 (RV) 压力过载和心力衰竭.
- 基于细胞的疗法,包括介质干细胞 (MSC) 和c-kit阳性细胞 (CPC),正在探索恢复心脏功能.
- 据信,这些细胞通过膜机制起作用,防止细胞亡并促进细胞健康.
研究的目的:
- 研究患病心脏对不同细胞疗法的蛋白质反应.
- 为了比较MSCs和各种CPC群体在逆转RV压力过载引起的蛋白质变化的有效性.
主要方法:
- 使用肺动脉带带 (PAB) 建立了RV压力过载的幼鼠模型.
- 骨髓衍生MSCs和三个CPC群体 (nCPCs,cCPCs,ES-CPCs) 被注射到RV自由壁中.
- 通过液体染色学-并联质谱学,系统生物学和生物信息学分析了RV功能,细胞保留和RV蛋白质组.
主要成果:
- 肺动脉带纹改变了5.97%的RV蛋白质组.
- MSC治疗逆转了72%的PAB改变的蛋白质组,其次是nCPCs (54%),ES-CPCs (52%) 和cCPCs (39%).
- MSC,nCPC和ES-CPC疗法与预测的心脏不良影响的减少有关.
结论:
- 在大鼠模型中,MSCs,ES-CPCs和nCPCs显著逆转了PAB诱导的蛋白质变化,导致病前状态.
- 基于细胞的疗法通过部分恢复心脏蛋白质组,显示出改善RV功能后压力过载的潜力.
更多相关视频
11:51Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
10.3K
10:18Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice
Published on: February 1, 2022
3.0K
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391